Figures & data
Figure 1. Sample selection flowchart. Abbreviations. AML: acute myeloid leukemia; CLL: chronic lymphocytic leukemia; ICD-9 CM: International Classification of Disease, 9th revision, Clinical Modification; ICD-10 CM: International Classification of Disease, 10th revision, Clinical Modification; LOT: line of therapy; SLL: small lymphocytic lymphoma; 1L: first-line; 2L: second-line; 3L+: third- or later-line. (a) Patients with an ibrutinib + venetoclax LOT at any moment were removed from study sample. (b) For patients with more than one line of venetoclax-based therapy, the index date was considered to be the date of the start of the first venetoclax-based LOT.
Table 1. Demographic and clinical characteristics during the 12-month baseline period prior to the initiation of venetoclax-based therapy.
Figure 2. Treatment sequencing among patients who received venetoclax (A) as 1L treatment (N = 25) (B) as 2L treatment (N = 30) and (C) as 3L treatment (N = 34)a. Abbreviations. CIT: chemoimmunotherapy; V: venetoclax; 1L: first-line; 2L: second-line; 3L: third-line. (a) Each concentric ring represents one line of therapy, with the most inner circle representing 1L therapy, the intermediate ring representing 2L therapy, and the outer ring representing 3L therapy.
